###### Clinical Perspective

What Is New?
============

-   In a prespecified analysis, COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) Diabetes compared low-dose rivaroxaban (2.5 mg twice daily) plus aspirin versus placebo plus aspirin in 6922 patients with stable coronary or peripheral artery disease and diabetes mellitus.

-   Although there was a consistent and similar relative risk reduction with rivaroxaban plus aspirin versus placebo plus aspirin in patients both with and without diabetes mellitus for the primary efficacy end point and all-cause mortality, notably, the absolute risk reductions appeared larger in patients with diabetes mellitus, including a 3-fold greater reduction in mortality.

-   There appeared to be a larger absolute net clinical benefit in those with diabetes mellitus.

What Are the Clinical Implications?
===================================

-   In patients with stable atherosclerosis and diabetes mellitus without an indication for dual antiplatelet therapy such as recent stenting or recent acute coronary syndromes, the addition of low-dose rivaroxaban to aspirin provides substantial reductions in ischemic events, including a significant reduction in all-cause mortality, with absolute risk reductions that appeared larger in those with versus without diabetes mellitus.

-   Non-fatal major bleeding was increased similarly in those with versus without diabetes mellitus.

-   In patients at acceptable bleeding risk, the addition of low-dose rivaroxaban to aspirin should be considered in the secondary prevention regimen of patients with atherosclerosis and diabetes mellitus.

**Editorial, see p 1855**

Diabetes mellitus is a commonly occurring major risk amplifier in patients with established atherosclerosis.^[@R1]--[@R4]^ In particular, those with polyvascular disease, a marker of significant clinical atherosclerotic burden, and concomitant diabetes mellitus, which frequently coexist, constitute a very high-risk group of patients subject to coronary, cerebral, and peripheral ischemic events.^[@R1],[@R5],[@R6]^ Lipid-lowering therapies and glycemia-modifying drugs can help attenuate this risk.^[@R7]--[@R18]^ Despite effective control of other risk factors, diabetes mellitus still contributes to a prothrombotic state and residual cardiovascular risk.^[@R19]^ Antiplatelet therapy, including dual antiplatelet therapy, has been established as effective across a wide variety of stable atherosclerotic patients, with some suggestion of heightened benefit in those with diabetes mellitus at baseline.^[@R20]--[@R29]^

More recently, a strategy of dual pathway antithrombotic therapy with an antiplatelet and a reduced-dose anticoagulant has been tested and shown to be effective.^[@R30]--[@R38]^ The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) demonstrated that aspirin plus rivaroxaban 2.5 mg twice daily was superior to aspirin plus rivaroxaban placebo for the reduction of ischemic events in 27 395 patients with coronary artery disease or peripheral artery disease. A significant reduction in cardiovascular death was seen with dual pathway inhibition, as well as lower all-cause mortality.

In the present prespecified analysis of COMPASS, we analyzed the results of rivaroxaban plus aspirin versus aspirin alone in the subgroups of patients with or without diabetes mellitus at baseline.

Methods
=======

The data that support the findings of this study may be made available from the corresponding author on reasonable request. The design and results of the overall COMPASS trial have been previously published. In brief, COMPASS was a multicenter, double-blind, randomized, placebo-controlled trial of 27 395 patients with a history of coronary artery disease or peripheral artery disease. Patients were randomized to aspirin plus rivaroxaban placebo, rivaroxaban (5 mg twice daily) plus aspirin placebo, or double antithrombotic therapy with aspirin plus rivaroxaban 2.5 mg twice daily. The primary outcome was cardiovascular death, myocardial infarction (MI), or stroke. Secondary end points included all-cause mortality and major adverse limb events. We also analyzed all major ischemic vascular events (cardiovascular death, MI, stroke, and major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding. The prespecified net clinical benefit was defined as MI, stroke, cardiovascular death, or bleeding leading to death or symptomatic bleeding into a critical organ. The protocol was approved by the relevant health authorities and institutional review boards. Written informed consent was required from all participants.

The trial was stopped early at the recommendation of the independent data and safety monitoring board because of the overwhelming efficacy of the rivaroxaban plus aspirin arm versus aspirin alone. This analysis focuses on the 18 278 patients in those 2 study groups and compares the outcomes in those with and those without diabetes mellitus according to the case history at baseline.

Statistical Analysis
--------------------

Analyses were conducted according to the intention-to-treat principle. We compared baseline characteristics of patients with and without diabetes mellitus at baseline using Wilcoxon 2-sample tests for continuous variables and Pearson χ^2^ tests for categorical variables. Survival analyses were based on the time to a first event. Kaplan-Meier risks at 36 months were calculated. We used stratified Cox proportional hazards regression models to estimate hazard ratios (HRs) and corresponding 95% CIs to compare the effects of antithrombotic regimens in patients with and without diabetes mellitus. Significance was tested with the use of stratified log-rank tests. The assumption of the proportional hazards was verified by use of the plots of the log of the negative log of survival function against the log of time. Interaction between the effect of treatment with rivaroxaban/aspirin and diabetes mellitus status was tested in a stratified Cox model fitted to all patients. The Gail-Simon test for qualitative interactions was used to test for interaction of absolute risk reduction, with the null hypothesis that not all of the subgroup reductions favored rivaroxaban plus aspirin. All reported *P* values are 2 sided. No adjustments were made for multiple subgroup or end-point comparisons; therefore, all results presented herein should be viewed as hypothesis generating. Analyses were performed with SAS software for Linux, version 9.4 (SAS Institute Inc, Cary, NC).

Results
=======

Of the 27 395 randomized patients with stable atherosclerosis in COMPASS, 10 341 had diabetes mellitus at enrollment and 17 054 did not. A total of 18 278 patients were randomized to the combination of rivaroxaban and aspirin or aspirin alone in the COMPASS trial. Of these, 6922 had diabetes mellitus at baseline and 11 356 did not have diabetes mellitus. Baseline characteristics of those with and without diabetes mellitus from the entire trial are shown in [Table I in the Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.046448), and those from the rivaroxaban plus aspirin and placebo plus aspirin arms are shown in Table [1](#T1){ref-type="table"}. Those with diabetes mellitus were significantly younger and more likely female; it is not surprising that there were several other significant differences between the 2 groups. [Table II in the Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.046448) shows the baseline characteristics in the rivaroxaban plus aspirin and rivaroxaban plus placebo arms in those with diabetes mellitus, and [Table III in the Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.046448) provides this information for those without diabetes mellitus.

###### 

Baseline Characteristics of Patients With and Without Diabetes Mellitus at Baseline Randomized to Rivaroxaban Plus Aspirin or to Placebo Plus Aspirin
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The primary efficacy end point for aspirin plus low-dose rivaroxaban versus aspirin plus rivaroxaban placebo in those with and without diabetes mellitus is shown in Figure [1](#F1){ref-type="fig"}. Table [2](#T2){ref-type="table"} provides several efficacy and safety comparisons. There was a consistent and similar relative risk reduction for benefit of rivaroxaban plus aspirin versus aspirin alone in patients with and without diabetes mellitus for the primary efficacy end point and the secondary end points, including mortality (Figure [2](#F2){ref-type="fig"}). However, because of their higher baseline risk, although the absolute risk reductions appeared larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (Kaplan-Meier event rates, 2.3% versus 1.4% for the primary end point at 3 years, Gail-Simon qualitative *P*~interaction~\<0.0001; 1.9% versus 0.6% for all-cause mortality, *P*~interaction~= 0.02); the respective number needed to treat for 3 years was 44 versus 73 and 54 versus 167.

###### 

Outcomes in Patients With and Without Diabetes Mellitus for Rivaroxaban Plus Aspirin Versus Placebo Plus Aspirin
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![**Cardiovascular death, myocardial infarction, or stroke.** Kaplan-Meier event curves for patients with and without diabetes mellitus randomized to aspirin plus placebo or aspirin plus low-dose rivaroxaban. The primary end point of cardiovascular death, myocardial infarction, or stroke is shown. Percentages are Kaplan-Meier risks at 3 years. ARR indicates absolute risk reduction; and HR, hazard ratio.](cir-141-1841-g003){#F1}

![**All-cause death.** Kaplan-Meier event curves for patients with and without diabetes mellitus randomized to aspirin plus placebo or aspirin plus low-dose rivaroxaban. The secondary end point of all-cause death is shown. Percentages are Kaplan-Meier risks at 3 years. ARR indicates absolute risk reduction; and HR, hazard ratio.](cir-141-1841-g004){#F2}

In an evaluation of the totality of ischemic events (cardiovascular death, stroke, MI, major adverse limb events, or major vascular amputation) at 3 years, those without diabetes mellitus at baseline had a significant reduction to 6.1% from 7.8% (HR, 0.74 \[95% CI, 0.62--0.89\]; *P*=0.001) with dual pathway antithrombotic therapy; in those with diabetes mellitus, the corresponding rates were 9.4% and 12.1% (HR, 0.73 \[95% CI, 0.61--0.88\]; *P*=0.0007; Table [2](#T2){ref-type="table"}). Although the HRs were similar, the absolute risk reductions were 1.7% and 2.7%, respectively (Gail-Simon qualitative *P*~interaction~\<0.0001; Figure [3](#F3){ref-type="fig"}). The respective number needed to treat for 3 years was 60 versus 38.

![**Major vascular events.** Kaplan-Meier event curves for patients with and without diabetes mellitus randomized to aspirin plus placebo or aspirin plus low-dose rivaroxaban. The expanded end point of all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events \[MALEs\], including amputation) is shown. Percentages are Kaplan-Meier risks at 3 years. ARR indicates absolute risk reduction; and HR, hazard ratio.](cir-141-1841-g005){#F3}

As in the trial overall, there was a significant increase in major bleeding with the dual pathway regimen in the subgroups with and without diabetes mellitus, with a similar degree of risk increase. In those without diabetes mellitus, major bleeding was increased at 3 years to 4.4% from 3.2% (HR 1.69 \[95% CI, 1.33--2.15\]; *P*\<0.0001). In those with diabetes mellitus, major bleeding was increased at 3 years to 4.5% from 3.4% (HR, 1.69 \[95% CI, 1.33--2.15\]; *P*=0.0006, *P*~interaction~=0.97). There were no significant increases in intracranial or fatal bleeding. The absolute net clinical benefit for dual pathway inhibition with our prespecified definition was numerically greater (2.7% versus 1.0%) in those with versus those without diabetes mellitus, although both subgroups derived similar benefit (Gail-Simon qualitative *P*~interaction~=0.001; Figure [4](#F4){ref-type="fig"}). In a nonprespecified post hoc analysis, major bleeding was combined with the primary efficacy end point, and this resulted in no significant difference between treatment arms in either those with or without diabetes mellitus (Table [2](#T2){ref-type="table"}). There was no significant interaction with randomization to proton pump inhibitor versus placebo on the increased risk of major bleeding with rivaroxaban in the patients with diabetes mellitus ([Table IV in the Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.046448)).

![**Net clinical benefit.** Kaplan-Meier event curves for patients with and without diabetes mellitus randomized to aspirin plus placebo or aspirin plus low-dose rivaroxaban. The net clinical benefit outcome (cardiovascular death, myocardial infarction \[MI\], stroke, fatal bleeding, or symptomatic bleeding into a critical organ) is shown. Percentages are Kaplan-Meier risks at 3 years. ARR indicates absolute risk reduction; and HR, hazard ratio.](cir-141-1841-g006){#F4}

Results were similar in those with diabetes mellitus treated with medications versus those with diabetes mellitus but not receiving diabetes mellitus medications at baseline (Table [3](#T3){ref-type="table"}). Consistent results were also seen in the patients with diabetes mellitus with or without a history of ischemic events (MI, unstable angina, stroke, transient ischemic attack) and with or without a history of revascularization (percutaneous coronary intervention, coronary artery bypass grafting, peripheral artery intervention, peripheral artery bypass surgery; Table [4](#T4){ref-type="table"}).

###### 

Outcomes in Patients With Diabetes Mellitus (Untreated and Treated With Hypoglycemic Agents) and Without Diabetes Mellitus for Rivaroxaban Plus Aspirin Versus Placebo Plus Aspirin
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###### 

Effect of Antithrombotic Therapies in Subgroups of Patients With Diabetes Mellitus

![](cir-141-1841-g008)

Discussion
==========

This prespecified analysis of COMPASS shows that patients with stable atherosclerosis with concomitant diabetes mellitus have similar relative but, because of their more dismal prognosis, numerically greater absolute risk reductions in ischemic events than those without diabetes mellitus. This greater absolute efficacy occurs without any incremental increase in major bleeding complications in those with versus those without diabetes mellitus. Thus, the net clinical benefit for irreversible outcomes appears greater in those with versus those without diabetes mellitus. This finding makes the use of dual pathway inhibition with aspirin plus low-dose rivaroxaban particularly attractive in this high-risk population.

Patients with atherosclerosis and diabetes mellitus are a very high-risk group. Despite several advances in different therapeutic areas such as lipid, blood pressure, and glycemic control, patients with diabetes mellitus continue to have high rates of recurrent ischemic events. The population of patients with diabetes mellitus studied in COMPASS represents a very broad representation of secondary prevention, including patients with coronary artery disease, peripheral artery disease, and carotid disease. Patients had prior ischemic events or stable atherosclerosis without such a history. Patients with a history of revascularization and those without prior revascularization were enrolled in COMPASS, and all these subgroups appeared to have a consistent benefit in the overall trial and in the patients with diabetes mellitus. This latter observation does distinguish these results from the multiple trials of dual antiplatelet therapy that also show significant benefit and suggest greater absolute risk reductions in those with diabetes mellitus but that have not demonstrated convincing benefit in as diverse a group of patients with atherosclerosis outside of those with prior ischemic events or prior stenting. It is worth noting, however, that ischemic event rates in patients with diabetes mellitus in COMPASS treated with aspirin plus low-dose rivaroxaban were still higher than the rate in those without diabetes mellitus treated with placebo. Thus, there is further room for residual risk reduction.

In the setting of diabetic primary prevention, aspirin has been found to be superior to placebo, even in the contemporary era, although predictably bleeding was increased.^[@R39]^ However, with careful patient selection, there are patients with diabetes mellitus without evident atherosclerosis who have a favorable net clinical benefit.^[@R40]--[@R42]^ Now, in the secondary prevention of patients with diabetes mellitus, it is also clear that intensifying the antithrombotic regimen beyond aspirin alone is warranted in patients who are at an acceptable risk of bleeding. Examination of the prespecified definition of net clinical benefit in COMPASS, consisting of irreversible harms, demonstrated significant benefit for dual pathway inhibition, whereas a post hoc definition of net clinical benefit incorporating all major bleeding did not demonstrate significant benefit. However, although major bleeding is important, it is not appropriate to weight it equivalently to MI, ischemic stroke, amputations, or certainly all-cause mortality.^[@R42]^

Limitations of this analysis include that it is a subgroup not specifically powered for efficacy or safety assessments, although the analysis was prespecified. The early stopping of the trial further limits the power of subgroup analysis, although the independent data and safety monitoring board felt that the trial needed to be stopped as a result of overwhelming efficacy, including a reduction in all-cause mortality that echoed a prior trial with this double antithrombotic regimen.^[@R43],[@R44]^ Nevertheless, sufficient statistical power was present to demonstrate a significant reduction in the primary end point in the overall trial and in those with and without diabetes mellitus, increasing confidence in the subgroup analyses presented herein. Another limitation is that diabetes mellitus was defined only by case history, and duration of diabetes mellitus was not captured in the case report form. Some prior studies of antiplatelet agents have shown a gradient of benefit among those treated with insulin versus oral medications versus diet only; however, insulin treatment was not captured.^[@R45],[@R46]^

Conclusions
===========

Aspirin plus low-dose rivaroxaban reduces major cardiovascular events versus aspirin alone in patients with stable atherosclerosis, regardless of the presence or absence of diabetes mellitus, although the absolute risk reductions are numerically larger in those with diabetes mellitus.

Sources of Funding
==================

The COMPASS study was funded by Bayer AG.
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